These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 8063617

  • 1. Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene.
    Ura H, Obara T, Nishino N, Tanno S, Okamura K, Namiki M.
    Jpn J Cancer Res; 1994 Jun; 85(6):633-8. PubMed ID: 8063617
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Point mutation at codon 12 of c-Ki-ras oncogene in human pancreatic neoplasms and normal human pancreas tissue].
    Cui Q, Wang Z, Chen J.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Jun; 16(3):201-5. PubMed ID: 7805165
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.
    Kikuchi T, Nagata Y, Abe T.
    J Neurooncol; 1997 Sep; 34(3):233-9. PubMed ID: 9258815
    [Abstract] [Full Text] [Related]

  • 5. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.
    Gbelcová H, Rimpelová S, Knejzlík Z, Šáchová J, Kolář M, Strnad H, Repiská V, D'Acunto WC, Ruml T, Vítek L.
    Lipids Health Dis; 2017 Dec 20; 16(1):250. PubMed ID: 29262834
    [Abstract] [Full Text] [Related]

  • 6. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, Greenberg NM, Kreisberg JI.
    Oncogene; 1999 Jul 15; 18(28):4120-30. PubMed ID: 10435593
    [Abstract] [Full Text] [Related]

  • 7. Differences in molecular biological, biological and growth characteristics between the immortal and malignant hamster pancreatic cells.
    Takahashi T, Moyer MP, Cano M, Wang QJ, Mountjoy CP, Sanger W, Adrian TE, Sugiura H, Katoh H, Pour PM.
    Carcinogenesis; 1995 Apr 15; 16(4):931-9. PubMed ID: 7728976
    [Abstract] [Full Text] [Related]

  • 8. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
    Sumi S, Beauchamp RD, Townsend CM, Pour PM, Ishizuka J, Thompson JC.
    Pancreas; 1994 Sep 15; 9(5):657-61. PubMed ID: 7809022
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of protein isoprenylation and p21ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells in vitro.
    Schulz S, Nyce JW.
    Cancer Res; 1991 Dec 15; 51(24):6563-7. PubMed ID: 1835900
    [Abstract] [Full Text] [Related]

  • 10. [Oncogene expression and point mutation in human pancreatic adenocarcinomas].
    Li DC, Liu TH.
    Zhonghua Bing Li Xue Za Zhi; 1992 Jun 15; 21(3):152-5. PubMed ID: 1477938
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin.
    Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC.
    Gastroenterology; 1992 Sep 15; 103(3):982-9. PubMed ID: 1499946
    [Abstract] [Full Text] [Related]

  • 12. Simvastatin inhibits protein isoprenylation in the brain.
    Ostrowski SM, Johnson K, Siefert M, Shank S, Sironi L, Wolozin B, Landreth GE, Ziady AG.
    Neuroscience; 2016 Aug 04; 329():264-74. PubMed ID: 27180285
    [Abstract] [Full Text] [Related]

  • 13. Differential activation of the c-Ki-ras-2 proto-oncogene in human colorectal carcinoma.
    Halatsch ME, Hirsch-Ernst KI, Weinel RJ, Kahl GF.
    Anticancer Res; 1998 Aug 04; 18(4A):2323-5. PubMed ID: 9703874
    [Abstract] [Full Text] [Related]

  • 14. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation.
    Miller AC, Kariko K, Myers CE, Clark EP, Samid D.
    Int J Cancer; 1993 Jan 21; 53(2):302-7. PubMed ID: 8425769
    [Abstract] [Full Text] [Related]

  • 15. 17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
    Bonapace IM, Addeo R, Altucci L, Cicatiello L, Bifulco M, Laezza C, Salzano S, Sica V, Bresciani F, Weisz A.
    Oncogene; 1996 Feb 15; 12(4):753-63. PubMed ID: 8632897
    [Abstract] [Full Text] [Related]

  • 16. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.
    Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ.
    Clin Cancer Res; 1999 Jan 15; 5(1):119-27. PubMed ID: 9918209
    [Abstract] [Full Text] [Related]

  • 17. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Klöppel G.
    Cancer; 1999 Apr 15; 85(8):1703-10. PubMed ID: 10223563
    [Abstract] [Full Text] [Related]

  • 18. Stability of ras oncogene mutation in the human tumor xenografts through serial passages.
    Kijima H, Abe Y, Yamazaki H, Ohnishi Y, Ueyama Y, Tamaoki N, Nakamura M.
    Anticancer Res; 1994 Apr 15; 14(6B):2583-7. PubMed ID: 7872685
    [Abstract] [Full Text] [Related]

  • 19. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma.
    Burmer GC, Rabinovitch PS, Loeb LA.
    Environ Health Perspect; 1991 Jun 15; 93():27-31. PubMed ID: 1773797
    [Abstract] [Full Text] [Related]

  • 20. Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients.
    Mariyama M, Kishi K, Nakamura K, Obata H, Nishimura S.
    Jpn J Cancer Res; 1989 Jul 15; 80(7):622-6. PubMed ID: 2507485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.